Imaging risankizumab in inflammatory bowel disease
Treatments studied
Part of Digestive system clinical trials.
This trial tests a new imaging method using a special dye (risankizumab-800CW) to see how risankizumab, a medicine for inflammatory bowel disease, works in the bowel. The goal is to better understand the medicine's effects and help doctors tailor treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with inflammatory bowel disease (IBD), like Crohn's disease or ulcerative colitis.
- Your IBD is currently active, meaning you have symptoms or a high stool test (calprotectin over 60).
- You are either a candidate for risankizumab therapy or have already been taking it for at least 14 weeks.
- You are scheduled for an endoscopy (a procedure to look inside your bowel).
- You are at least 18 years old and can give informed consent.
- You are not pregnant, breastfeeding, or planning to become pregnant during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses special fluorescent versions of adalimumab and risankizumab to see inflammation in the bowel during an endoscopic procedure. It may help find out which treatment works best for each person's inflammation.
This study tests a medicine called tirzepatide to see if it can help people with active Crohn’s disease who have not responded to multiple prior treatments. It focuses on how the drug might work beyond just reducing inflammation.
This study tests a new medicine called mirikizumab for people with ulcerative colitis or Crohn's disease who have not responded well to other treatments. It aims to see if mirikizumab can help control symptoms and improve quality of life.
This study uses a special “light tracer” medicine with adalimumab to see where inflammation is in the gut (IBD) or joints (RA). If you have active disease, it may help doctors better target treatment by showing inflammation more clearly during scans.
This study tests risankizumab (a medication that targets inflammation) in young people with ulcerative colitis who haven't improved enough on other treatments. It aims to see if risankizumab can help control symptoms and reduce bowel inflammation.
This study observes how well risankizumab works for people with moderate to severe ulcerative colitis who are already starting it as part of their regular care. It helps doctors learn more about the drug's real-world effects.
Hear when a new Ulcerative Colitis (UC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.